[1] 中华人民共和国国家卫生健康委员会.输血医学术语[S].2020. [2] PADMANABHAN A,CONNELLY-SMITH L,AQUI N,et al.Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the American society for apheresis:the eighth special issue[J]. J Clin Apher,2019,34(3):171-354. [3] IPE T S,MARQUES M B.Vascular access for therapeutic plasma exchange[J]. Transfusion,2018,58(Suppl 1):580-589. [4] ARMENDARIZ T Jr,WEST J,OLSON D M,et al.Is a 20 gauge fenestrated intravenous catheter non-inferior to a 18 gauge standard catheter for apheresis procedures? A pilot study[J]. J Clin Apher,2021,36(4):606-611. [5] BAMBI F,FONTANAZZA S,MESSERI A,et al.Use of percutaneous radial artery catheter for peripheral blood progenitor cell collection in pediatric patients[J]. Transfusion,2003,43(2):254-258. [6] KHATRI B O.Vascular access via temporary radial artery catheterization for therapeutic plasma exchange[J]. J Clin Apher,2003,18(3):134. [7] GALLIENI M,BRENNA I,BRUNINI F,et al.Dialysis central venous catheter types and performance[J]. J Vasc Access,2014,15(Suppl 7):S140-S146. [8] 中华人民共和国国家卫生健康委员会.血液净化标准操作规程2021版[S].2021. [9] GOLESTANEH L,MOKRZYCKI M H.Vascular access in therapeutic apheresis:update 2013[J]. J Clin Apher,2013,28(1):64-72. [10] WALSER E M.Venous access ports:indications,implanta tion technique,follow-up,and complications[J]. Cardiova sc Intervent Radiol,2012,35(4):751-764. [11] STEGMAYR B,PTAK J,WIKSTRÖM B,et al. World apheresis registry 2003-2007 data[J]. Transfus Apher Sci,2008,39(3):247-254. [12] GÜLLE S,BAK M,SERDAROGLU E,et al. Low-density lipoprotein apheresis by membrane differential filtration (cascade filtration) via arteriovenous fistula performed in children with familial hypercholesterolemia[J]. Ther Apher Dial,2010,14(1):87-92. [13] Ikizler T A.Arteriovenous fistulas in patients with kidney transplantation[J]. Kidney Int,2020,97(1):20-21. [14] MAYA I D,O'NEAL J C,YOUNG C J,et al. Outcomes of brachiocephalic fistulas,transposed brachiobasilic fistulas,and upper arm grafts[J]. Clin J Am Soc Nephrol,2009,4(1):86-92. [15] MÖRTZELL HENRIKSSON M,NEWMAN E,WITT V,et al. Adverse events in apheresis:an update of the WAA registry data[J]. Transfus Apher Sci,2016,54(1):2-15. [16] Winters. Therapeutic Apheresis: A Physician's Handbook[J]. Lange Medical Library, 2011, 35(10):132-135. [17] Weinstein R.Jones HG BN: Management of the therapeutic apheresis patient. In: Aheresis: Principles and practice[M]. 2nd edn. McLeod BC PT,2003: 253-282. [18] AGREDA-VÁSQUEZ G P,ESPINOSA-POBLANO I,SÁNCHEZ-GUERRERO S A,et al. Starch and albumin mixture as replacement fluid in therapeutic plasma exchange is safe and effective[J]. J Clin Apher,2008,23(5):163-167. [19] DAVID U.Modern blood banking & transfusion practices,5th edition[book review[J]. Aust J Med Sci,2006,27(3):123-124. [20] STEGMAYR B,NEWMAN E,WITT V,et al.Using the world apheresis association registry helps to improve the treatment quality of therapeutic apheresis[J]. Transfus Med Hemother,2021,48(4):234-239. [21] TOSS F,EDGREN G,BERLIN G,et al.Does prophylactic calcium in apheresis cause more harm than good? - Centre heterogeneity within the World Apheresis Association Register prevents firm conclusions[J]. Vox Sang,2018,113(7):632-638. [22] 中华医学会重症医学分会. 低血容量休克复苏指南(2007)[J]. 中国实用外科杂志,2007,27(8):581-587. [23] CARDONA V,ANSOTEGUI I J,EBISAWA M,et al.World allergy organization anaphylaxis guidance 2020[J]. World Allergy Organ J,2020,13(10):100472. [24] PEPE J,COLANGELO L,BIAMONTE F,et al.Diagnosis and management of hypocalcemia[J]. Endocrine,2020,69(3):485-495. [25] 中华人民共和国卫生和计划生育委员会.造血干细胞移植技术管理规范(2017版)[S].2017. [26] 中国输血协会临床输血管理学专业委员会. 自体富血小板血浆制备技术专家共识[J]. 中国输血杂志,2021,34(7):677-683. [27] 中华人民共和国卫生部.全血及成分血质量要求[S].2012. [28] KIM S H,KIM W,HUH S Y,et al.Clinical efficacy of plasmapheresis in patients with neuromyelitis optica spectrum disorder and effects on circulating anti-aquaporin-4 antibody levels[J]. J Clin Neurol,2013,9(1):36-42. [29] CHOI M H,CHOE Y H,PARK Y,et al.The effect of therapeutic leukapheresis on early complications and outcomes in patients with acute leukemia and hyperleukocytosis:a propensity score-matched study[J]. Transfusion,2018,58(1):208-216. [30] DAVER N,KANTARJIAN H,MARCUCCI G,et al.Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis[J]. Br J Haematol,2015,168(5):646-653. [31] 中华医学会血液学分会白血病淋巴瘤学组. 真性红细胞增多症诊断与治疗中国指南(2022年版)[J]. 中华血液学杂志,2022,43(7):537-541. [32] 中华人民共和国国家质量监督检验检疫总局,中国国家标准化管理委员会.医院消毒卫生标准[S].2012. [33] 中华人民共和国卫生部.血源性病原体职业接触防护导则[S].2009. [34] 中华人民共和国国家卫生健康委员会.医务人员手卫生规范[S].2020. [35] 中华人民共和国国务院.医疗废物管理条例[S].2003. [36] 国家环保局.医疗废物专用包装物、容器标准和警示标识规定[S].2003. |